-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly Agrees to Buy Calytrix Bio in up to $1.5 Billion Deal

MT Newswires·11/16/2026 08:02:01
Listen to the news
08:02 AM EST, 11/16/2026 (MT Newswires) -- Eli Lilly (LLY.F, LLY.SW) agreed to acquire US biotechnology company Calytrix Bio, according to a Monday release. The US pharmaceutical company could pay up to $1.5 billion in cash, including upfront and additional clinical and regulatory milestone payments. The acquisition will expand Eli Lilly's pipeline of treatments for rare blood cancers known as myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis.